MedTrace Logo

The MAD Study of SSGJ-613 in Healthy Subjects

NCT05966701 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2023-08-01

No results posted yet for this study

Summary

To evaluate the safety and tolerability of SSGJ-613 after multiple subcutaneous injections in healthy subjects.

Conditions

  • Arthritis, Gouty

Interventions

DRUG

SSGJ-613

SSGJ-613 subcutaneous injection.

DRUG

Placebo

Placebo subcutaneous injection.

Sponsors & Collaborators

  • Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Qinghong Zhou, BS · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

  • Qian Chen, PhD · Shanghai Xuhui District Central Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-08-10
Primary Completion
2024-03-10
Completion
2024-03-10

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05966701 on ClinicalTrials.gov